Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbhfiledCriticalNycomed Gmbh
Priority to CU20040176ApriorityCriticalpatent/CU23370A3/en
Publication of CU23370A3publicationCriticalpatent/CU23370A3/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describen formas de dosificación para administración oral de un inhibidor de PDE 4 cuya solubilidad es ligera. Contienen PVP como aglutinante.Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as a binder.
CU20040176A2004-08-172004-08-17
ORAL DOSE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE INGREDIENT AND POLYVINROL PIRROLIDONE AS EXCIPIENT
CU23370A3
(en)
Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.
DERIVATIVES OF N '- (PHENYL) -N- (MORFOLIN-4-IL-PIRIDIN-2-IL) -PIRIMIDINA-2, 4-DIAMINE AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE AFFECTIONS